

---

# BIOCHEMICAL PHARMACOLOGY AND TOXICOLOGY

---

## Volume I Methodological Aspects of Drug Metabolizing Enzymes

*Edited by*  
**DAVID ZAKIM**

*and*  
**DONALD A. VESSEY**



1987年12月21日

---

# BIOCHEMICAL PHARMACOLOGY AND TOXICOLOGY

---

## Volume I Methodological Aspects of Drug Metabolizing Enzymes

*Edited by*

**DAVID ZAKIM**

*Cornell University Medical College  
New York, New York*

*and*

**DONALD A. VESSEY**

*Veterans Administration Medical Center  
San Francisco, California*



A Wiley-Interscience Publication

**JOHN WILEY & SONS**

New York · Chichester · Brisbane · Toronto · Singapore

# BIOCHEMICAL PHARMACOLOGY AND TOXICOLOGY

Volume I

Copyright © 1985 by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

## Library of Congress Cataloging in Publication Data:

Main entry under title:

Biochemical pharmacology and toxicology.

"A Wiley-Interscience publication."

Contents: v. 1. Methodological aspects of drug metabolizing enzymes.

1. Pharmacology—Addresses, essays, lectures.
  2. Biological chemistry—Addresses, essays, lectures.
- I. Zakim, David. II. Vessey, Donald A.

RM300.B55 1985 612'.015 85-656

ISBN 0-471-86793-4 (v. 1)

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

---

## LIST OF CONTRIBUTORS

---

THOMAS D. BOYER, M.D.  
Veterans Administration  
Medical Center  
Department of Medicine  
University of California  
San Francisco, California

BRUCE HAMMOCK, Ph.D.  
Departments of Entomology  
and Environmental  
Toxicology  
University of California  
Davis, California

YEHOSUA HOCHMAN, Ph.D.  
Division of Digestive Diseases  
Department of Medicine

Cornell University Medical  
College  
New York, New York

WILLIAM C. KENNEY, Ph.D.  
Protein Purification Laboratory  
AMGen  
Thousand Oaks, California

JULIAN A. PETERSON, Ph.D.  
Department of Biochemistry  
Southwestern Graduate  
School of Biomedical  
Sciences  
The University of Texas  
Health Science Center  
Dallas, Texas



RUSSELL A. PROUGH, PH.D.  
Department of Biochemistry  
Southwestern Graduate  
School of Biomedical  
Sciences  
The University of Texas  
Health Science Center  
Dallas, Texas

SANFORD S. SINGER, PH.D.  
Department of Chemistry  
University of Dayton  
300 College Park Avenue  
Dayton, Ohio

THOMAS P. SINGER, PH.D.  
Departments of  
Pharmacuetical Chemistry,  
Biochemistry and Biophysics  
University of California  
San Francisco, California  
and  
Molecular Biology Division  
Veterans Administration  
Medical Center  
San Francisco, California

DONALD A. VESSEY, PH.D.  
Departments of Medicine and  
Pharmacology  
University of California  
and  
Liver Study Unit  
Veterans Administration  
Medical Center  
San Francisco, California

ROGER N. WIXTROM  
Departments of Entomology  
and Environmental  
Toxicology  
University of California  
Davis, California

DAVID ZAKIM, M.D.  
Division of Digestive Diseases  
Department of Medicine  
Cornell University Medical  
College  
New York, New York

---

## SERIES PREFACE

---

The total number of known chemical compounds exceeds 6 million and is increasing at the rate of 25,000 per month. The number of chemical compounds to which humans are commonly exposed is estimated to be in excess of 60,000 and is increasing in number and diversity. Given that many new chemical compounds have been discovered to have unanticipated toxicities, the increasing chemical diversity in our environment presents a substantial health threat to us and to other living things. Greater predictability is needed and will come only through a basic understanding of the target systems and the nature of their interaction with the xenobiotic.

We believe that the need to understand this increasing chemical challenge to biological systems will stimulate research in this area. This research will involve the application of basic biochemistry to the study of important pharmacological and toxicological problems. Because investigators in these fields are led to the study of biochemical systems that are new to them, there is a need for a treatise to introduce investigators in a practical way to the biochemistry of those systems.

It is the aim of this series to address the basic biochemistry of a number of systems of interest to pharmacologists and toxicologists. We intend to provide a fundamental understanding of the areas presented and to develop a working knowledge by providing methodological details. Further, it is hoped that these presentations will encourage research into these areas by focusing attention on significant unresolved issues.

DONALD A. VESSEY  
DAVID ZAKIM

*San Francisco, California*  
*April 1985*

---

## PREFACE

---

Biological systems have evolved enzymes that detoxify naturally occurring toxins as well as a variety of compounds added to the environment by our industrial society. Alternatively, these enzymes occasionally catalyze reactions that lead to a metabolic activation of compounds to toxins. In both situations the xenobiotic metabolizing enzymes are affecting the health and survival of the organism.

The lack of knowledge of the detailed properties of enzymes that modify the biological activity of endogenous and exogenous chemicals underlies many problems in toxicology and therapeutics. The administration of a drug or toxin in amounts that exceed an animal's metabolic capacity can lead to a serious, if not fatal, disease. A more significant and frequent clinical problem is the unpredictable and untoward reaction to a therapeutic dose of a drug, especially in geriatric patients or those on polypharmacy regimens. These kinds of reactions, which may account for as much as 10% of all hospital admissions in the United States, can often be traced with certainty to competition between drugs for a common detoxification pathway. It is likely that most of these



reactions will eventually be understood in this context. In addition, the need to detoxify small amounts of environmental pollutants could be affected by therapeutic agents and vice versa.

It is clear, therefore, that understanding the kinetic properties of the xenobiotic metabolizing enzymes, the manner in which they are regulated, their multiplicity and the chemical basis for their substrate specificities, will have a significant, positive effect on the value of medical intervention. It is also recognized that understanding the induction of xenobiotic metabolizing enzymes may have practical medical significance. It is certain that a great deal of new knowledge relevant to basic biology and biochemistry will come from studies of xenobiotic metabolizing enzymes.

The number of investigators interested in studying xenobiotic metabolizing enzymes continues to increase. However, most of these enzymes have a complexity that often serves to deter investigators who might otherwise wish to work in this area or, at least, limits the depth of their enquiry. These complexities exist because such enzymes differ from simple soluble fraction enzymes in that generally they are tightly bound to membranes, they have very broad substrate specificities, there are multiple molecular forms of each enzyme, their substrates are relatively insoluble in water, and their kinetic properties are often complex. In this volume we have focused our attention on those drug metabolizing enzymes that possess these complexities. The enzymes addressed are: the epoxide hydratases, the sulfotransferases, the UDP-glucuronyl-transferases, the monoamine oxidases, the cytochromes P450, and the glutathione S-transferases.

In writing about each of these enzymes, the authors have endeavored to provide sufficient basic information to allow the reader to approach the current research literature with understanding. They have also included lengthy discussions of the methods currently used to characterize the enzymes and the limitations and pitfalls associated with these methods. The aim has been to provide a fundamental treatise that will not only introduce people to the varied aspects of the study of these enzymes but also provide the necessary details for actually undertaking such investigations. We feel fortunate having found authors who feel

the same need for such a text and who possess the high level of scholarship necessary to undertake this endeavor. We thank John Wiley & Sons for providing us with this opportunity.

DONALD A. VESSEY  
DAVID ZAKIM

*San Francisco, California*  
*April 1985*

---

# CONTENTS

---

1. **Membrane-Bound and Soluble Fraction Epoxide Hydrolases: Methodological Aspects** 1  
*Roger N. Wixtrom and Bruce D. Hammock*
2. **Preparation and Characterization of the Different Kinds of Sulfotransferases** 95  
*Sanford S. Singer*
3. **Methods for Characterizing the Function of UDP-Glucuronyltransferases** 161  
*David Zakim, Donald A. Vessey, and Yehosua Hochman*
4. **Mitochondrial Monoamine Oxidase: Isolation, Assay, Properties, Mechanism, and Unresolved Questions** 229  
*Thomas P. Singer*

---

<b>5. Measurement of Cytochrome P-450 Related Enzyme Activities</b>	<b>265</b>
<i>Russell A. Proough and Julian A. Peterson</i>	
<hr/>	
<b>6. Preparation, Characterization, and Properties of Glutathione S-Transferases</b>	<b>297</b>
<i>Thomas D. Boyer and William C. Kenney</i>	
<hr/>	
<b>Index</b>	<b>365</b>

# MEMBRANE-BOUND AND SOLUBLE-FRACTION EPOXIDE HYDROLASES

## Methodological Aspects

**ROGER N. WIXTROM**

**BRUCE D. HAMMOCK**


*Departments of Entomology and Environmental Toxicology  
University of California  
Davis, California*

1.	Introduction	4
2.	Subcellular Distribution of Epoxide Hydrolases	6
2.1	Distribution in Normal Tissue	6



2.2	The Preneoplastic Antigen	12
3.	Properties of the Major Forms of Epoxide Hydrolase	15
3.1.	Substrate Specificity	15
3.1.1.	General Information	15
3.1.2.	Specificity of the Microsomal Epoxide Hydrolase	16
3.1.3.	Specificity of the Cytosolic Epoxide Hydrolase	18
3.1.4.	Specificity of the Cholesterol Epoxide Hydrolase	20
3.1.5.	Diagnostic Substrates	21
3.2.	Induction	21
3.2.1.	Induction of the Microsomal Epoxide Hydrolase	21
3.2.2.	Induction of the Cytosolic Epoxide Hydrolase	24
3.2.3.	Induction of the Cholesterol Epoxide Hydrolase	25
3.3.	Inhibition	25
3.3.1.	General Information	25
3.3.2.	Inhibition of the Microsomal Epoxide Hydrolase	26
3.3.3.	Inhibition of the Cytosolic Epoxide Hydrolase	28
3.3.4.	Inhibition of the Cholesterol Epoxide Hydrolase	31
3.4.	Stimulation	31
3.5.	Purification	32
3.5.1.	Purification of the Microsomal Epoxide Hydrolase	32
3.5.2.	Purification of the Cytosolic Epoxide Hydrolase	33
4.	Tissue Distribution	35
5.	Variation Among Species, Age, Sex, and Strain	36
6.	Analytical Methods	37
6.1.	General Information	37
6.1.1.	Selecting the Appropriate Assay	37
6.1.2.	Verification of the Identity of Products	39
6.1.3.	Potential Problems	41
6.2.	Colorimetric Methods	42
6.3.	Chromatographic Detection	43
6.3.1.	Thin-Layer Chromatography	43
6.3.2.	High-Pressure Liquid Chromatography	51


6.3.3.	Gas-Liquid Chromatography	52
6.4.	Solvent Partition Methods	56
6.4.1.	General Considerations	56
6.4.2.	Assays with Styrene Oxide	57
6.4.3.	Assays with Arene Oxides, Steroid Oxides, and Related Compounds	64
6.4.4.	Assays with Juvenile Hormone	65
6.4.5.	Assays with $\beta$ -Alkylstyrene Oxides	66
6.4.6.	Assays with Stilbene Oxides	68
6.4.7.	Designing a Partition Assay	71
6.5.	Continuous Spectrophotometric and Fluorometric Assays	76
6.6.	Immunochemical Methods for Measuring Enzyme Levels	80
References		81



## 1. INTRODUCTION


Epoxides are highly strained three-membered cyclic ethers which vary considerably in reactivity (Figure 1). The toxicity of these compounds often is related directly to their reactivity, and many of the electrophilically reactive epoxides are mutagenic, carcinogenic, or cytotoxic.<sup>1</sup>

The occurrence of epoxides is widespread. They are formed *in vivo* in several important biosynthetic pathways and as metabolites of xenobiotics. Leukotriene A<sub>4</sub> (2)<sup>2</sup> and squalene 2,3-oxide (1j)<sup>3,4</sup> are two examples of epoxidized biosynthetic intermediates. Numerous olefinic and aromatic xenobiotics, including many drugs used clinically, are metabolized to epoxides by microsomal cytochrome P-450-dependent monooxygenases,<sup>5</sup> and epoxides may also be formed by peroxide rearrangement. Two well-known examples of xenobiotics metabolized to epoxides are aflatoxin B<sub>1</sub> (3)<sup>1</sup> and benzo (a)pyrene (see 1h). Many natural products contain epoxides, including mycotoxins such as the 12,13-epoxytrichothecenes which are important contaminants of animal and human foodstuffs.<sup>6</sup> Epoxides are also used extensively in industry as intermediates and stabilizers. Manson has provided an extensive review of the vast number of epoxides to which humans are exposed.<sup>7</sup>



1

Epoxide hydrolases (EC 3.3.2.3)—formerly named epoxide hydrases or epoxide hydratases (EC 4.2.1.63)—catalyze the conversion of epoxides to 1,2 diols. The diols resulting from such hydration are more polar, more readily excretable, and generally represent a detoxification process. However, the diols of certain polycyclic aromatic hydrocarbons can be metabolized further by



**Figure 1.** Commonly used substrates of epoxide hydrolases. HEOM = 1,2,3,4,9,9-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-1,4-endo-methanonaphthalene. R 20458 = 1-(4'-ethylphenoxy)-3,7-dimethyl-6,7-epoxy-2E-octene. Note: Epoxides may be named as either the oxide of an alkane (e.g., octane 1,2-oxide) or trivially as the oxide of an alkene (e.g., octene oxide). Both methods of nomenclature have been used extensively in the literature.